Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BGI Genomics Co., Ltd.
BGI Genomics sells DNA sequencing and genetic testing services to hospitals, research labs, and medical institutions.
BGI Genomics is a Chinese company that reads DNA for a living. Hospitals, universities, and research institutes send it blood, tissue, or other samples, and the company sequences the genetic code inside them and turns that raw data into something useful — a diagnosis, a research result, or a screening report.
Its main business is genomic diagnosis: tests that help doctors detect inherited diseases, screen pregnancies for abnormalities, and guide cancer treatment. It also runs a large research-services arm, essentially acting as an outsourced sequencing lab for academic and medical researchers who need gene data but don't own the expensive machines. The pitch is simple — sequencing machines cost a fortune and require specialized staff, so it's often cheaper to rent the expertise than build it. BGI Genomics grew out of BGI Group, the Chinese genomics giant that made a name for itself contributing to the international Human Genome Project, and it was spun onto the Shenzhen exchange in 2017. The company sits in a crowded, fast-moving field. It competes with global sequencing-tools makers and diagnostics players, and its own former parent remains a major related party. A big chunk of its opportunity — and its risk — comes from China's massive population and its growing appetite for genetic screening, balanced against price pressure from government procurement and the reality that many genetic tests are becoming commodities. International expansion matters too, since overseas labs and hospitals pay in stronger currencies and offer growth beyond a fiercely competitive home market.
The core tension is that BGI Genomics is a service business built on top of machines and chemistry it doesn't fully control, so it lives or dies on volume, cost per test, and keeping its technology current. It spends heavily on research and development and on expanding its testing menu, because the winners in this industry are the ones who can offer more tests at lower prices. In short: a lab coat business that sells certainty — the answer to "what's in my genes?" — to the people who need it most.
Saved answer · last researched 14 Nov 2026